Dipeptidyl peptidase 4 inhibitors for the treatment of type 2 diabetes mellitus

Cover Page

Cite item

Full Text

Abstract

Type 2 diabetes mellitus is one of the most common endocrine diseases. This article discusses the new classes of antihyperglycemic agents (dipeptidyl peptidase 4 inhibitors, glucagon-like peptide-1 receptor agonists and sodium-glucose cotransporter-2 inhibitors), the approaches for prescription these drugs. The article also discusses the cardiovascular safety of new antihyperglycemic agents.

About the authors

T. B Morgunova

I.M.Sechenov First Moscow State Medical University of the Ministry of Health of the Russian Federation

Email: tanmorgun@mail.ru
канд. мед. наук, доц. каф. эндокринологии ГБОУ ВПО Первый МГМУ им. И.М.Сеченова 119991, Russian Federation, Moscow, ul. Trubetskaia, d. 8, str. 2

V. V Fadeev

I.M.Sechenov First Moscow State Medical University of the Ministry of Health of the Russian Federation

д-р мед. наук, зав. каф. эндокринологии ГБОУ ВПО Первый МГМУ им. И.М.Сеченова 119991, Russian Federation, Moscow, ul. Trubetskaia, d. 8, str. 2

References

  1. Godinho R, Mega C, Teixeira de Lemos E et al. The Place of Dipeptidyl Peptidase-4 Inhibitors in Type 2 Diabetes Therapeutics: A "Me Too" or "the Special One" Antidiabetic Class? J Diabetes Res 2015; 2015: 806979. doi: 10.1155/2015/806979. Epub 2015 May 17. Review.
  2. Дедов И.И., Шестакова М.В., Галстян Г.Р. и др. Алгоритмы специализированной медицинской помощи больным сахарным диабетом. Под ред. И.И.Дедова, М.В.Шестаковой (7-й выпуск). Сахарный диабет. 2015; 18 (1S): 1-112.
  3. Inzucchi S.E, Bergenstal R.M, Buse J.B et al. Management of hyperglycemia in type 2 diabetes: a patient - centered approach: position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care 2012; 35: 1364-79.
  4. Seino Y, Yabe D. Alogliptin benzoate for the treatment of type 2 diabetes. Exp Opin Pharmacother 2014; 15 (6): 851-63. doi: 10.1517/14656566.2014.898750.
  5. Christopher R, Covington P, Davenport M et al. Pharmacokinetics, pharmacodynamics, and tolerability of single increasing doses of the dipeptidylpeptidase-4 inhibitor alogliptin in healthy male subjects. Clin Ther 2008; 30: 513-27.
  6. Pratley R.E, Kipnes M.S, Fleck P.R et al. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor alogliptin in patients with type 2 diabetes inadequately controlled by glyburide monotherapy. Diabetes Obes Metab 2009; 11: 167-76.
  7. Pratley R.E, Reusch J.E, Fleck P.R et al. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor alogliptin added to pioglitazone in patients with type 2 diabetes: a randomized, doubleblind, placebo - controlled study. Curr Med Res Opin 2009; 25: 2361-71.
  8. Rosenstock J, Rendell M.S, Gross J.L et al. Alogliptin added to insulin therapy in patients with type 2 diabetes reduces HbA(1C) without causing weight gain or increased hypoglycaemia. Diabetes Obes Metab 2009; 11: 1145-52.
  9. Nauck M.A, Ellis G.C, Fleck P.R et al. Efficacy and safety of adding the dipeptidyl peptidase-4 inhibitor alogliptin to metformin therapy in patients with type 2 diabetes inadequately controlled with metformin monotherapy: a multicentre, randomised, double - blind, placebo - controlled study. Int J Clin Pract 2009; 63: 46-55.
  10. Del Prato S, Camisasca R, Wilson C, Fleck P. Durability of the efficacy and safety of alogliptin compared to glipizide over 2 years when used in combination with metformin. Diabetes Obes Metab 2014; 16 (12): 1239-46. doi: 10.1111/dom.12377. Epub 2014 Sep 25.
  11. De Fronzo R.A, Fleck P.R, Wilson C.A, Mekki Q. Alogliptin Study 010 Group. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor alogliptin in patients with type 2 diabetes and inadequate glycemic control: a randomized, double - blind, placebo - controlled study. Diabetes Care 2008; 31: 2315-7.
  12. Stratton I.M, Adler A.I, Neil H.A et al. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ 2010; 321: 405-12.
  13. UKPDS Group. Intensive blood - glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group. Lancet 1998; 352: 837-53.
  14. Gerstein H.C, Miller M.E, Byington R.P et al. Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med 2008; 358: 2545-59.
  15. Kahn S.E, Haffner S.M, Heise M.A et al. Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy. N Engl J Med 2006; 355 (23): 2427-43.
  16. Seck T, Nauck M, Sheng D et al. Safety and efficacy of treatment with sitagliptin or glipizide in patients with type 2 diabetes inadequately controlled on metformin: a 2- year study. Int J Clin Pract 2010; 64 (5): 562-76. doi: 10.1111/j.1742- 241.2010.02353.x.
  17. Göke R, Bader G, Dworak M. Real - life effectiveness and tolerability of vildagliptin and other oral glucose - lowering therapies in patients with type 2 diabetes in Germany. Diabetes Ther 2014; 5 (1): 183-91. doi: 10.1007/s13300-014-0060-4. Epub 2014 Mar 19.
  18. Gallwitz B, Rosenstock J, Rauch T et al. 2-year efficacy and safety of linagliptin compared with glimepiride in patients with type 2 diabetes inadequately controlled on metformin: a randomised, double - blind, non - inferiority trial. Lancet 2012; 380 (9840): 475-83. doi: 10.1016/S0140-6736(12)60691-6. Epub 2012 Jun 28.
  19. Matthews D.R, Dejager S, Ahren B et al. Vildagliptin add - on to metformin produces similar efficacy and reduced hypoglycaemic risk compared with glimepiride, with no weight gain: results from a 2-year study. Diabetes Obes Metab 2010; 12 (9): 780-9. doi: 10.1111/j.1463-1326.2010.01233.x.
  20. Mishriky B.M, Cummings D.M, Tanenberg R.J. The efficacy and safety of DPP4 inhibitors compared to sulfonylureas as add - on therapy to metformin in patients with Type 2 diabetes: A systematic review and meta - analysis. Diabetes Res Clin Pract 2015; 109 (2): 378-88. doi: 10.1016/j.diabres.2015.05.025. Epub 2015 May 14. Review.
  21. FDA Guidance for Industry. Diabetes mellitus - evaluating cardiovascular risk in new antidiabetic therapies to treat type 2 diabetes. www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ucm071627.pdf
  22. White W.B, Cannon C.P, Heller S.R et al. Alogliptin after acute coronary syndrome in patients with type 2 diabetes. N Engl J Med 2013; 369: 1327-35.

Copyright (c) 2016 Consilium Medicum

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies